IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
If you’re looking to outsource drug product development to a CDMO, you need a collaborative partner who will engage you deeply to understand the unique needs of your project.
From pre-formulation to commercial manufacturing and packaging, you can trust Cambrex to deliver your complex dosage forms with the perfect combination of technology, expertise, and collaboration.
At Cambrex, we offer a tried and trusted approach to technology transfer, for scale-up or when transitioning to a different facility.
We are equipped to take on projects at any size or scale, offering established pediatric formulation and development expertise and to-scale manufacturing capabilities.
Biopharma companies at all stages of development, rely on our expertise and broad capabilities to produce the clinical trial supply of drug products they need, when they need them.
We can support you, at any size or stage, with a range of primary and secondary packaging solutions.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
11.08.2010
East Rutherford, NJ – Cambrex Corporation’s (NYSE: CBM, “Cambrex”) President and CEO, Steven M. Klosk, will be honored by New York Law School on November 10th at the school’s 2010 Gala Celebration. Mr. Klosk and two others will be co-honored for uniquely personifying the core values of the school.
Mr. Klosk, a 1987 graduate of New York Law School’s evening division, will be awarded for both personally and professionally Embracing Innovation, a key focus of the school’s legal training.
Mr. Klosk joined Cambrex in 1992, and has held various executive positions including Chief Operating Officer, and was appointed President & CEO in 2008. Under Steve’s leadership, Cambrex has increased its focus on research and development in order to accelerate the number of novel products and services that Cambrex provides. The business has acquired or licensed access to several additional innovative technologies that are making Cambrex a leading provider of products and services to the pharmaceutical industry.
“I am honored to be recognized by New York Law School, and delighted to show my support to the school in appreciation of the outstanding education I received there. My experience at New York Law played a critical role in developing the foundation for my career in business. I was given the opportunity to be surrounded by very smart, very hardworking faculty and peers in an environment that fostered creative and analytical thinking. At Cambrex, creating value for our customers and the life sciences industry through technology and innovation is the key to growing in a highly competitive global market,” said Mr. Klosk.
Proceeds from the Gala celebration will be used to fund scholarships for talented law students and support the students and programming of the Diane Abbey Law Center for Children and Families. To learn more about the 2010 New York Law School Gala, please visit www.nyls.edu or call 212.431.2800.
Our newsletter
Thank you for subscribing up to our newsletter.